SIP
LCTX icon

Stoneridge Investment Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Stoneridge Investment Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,540
Closed -$20K – 172
2026
Q1 		$20K Hold
12,540
– – 0.01% 128
2025
Q4 		$21K Buy
+12,540
New +$21.7K 0.01% 126
2025
Q2 		– Sell
-10,712
Closed -$5K – 145
2025
Q1 		$5K Hold
10,712
– – ﹤0.01% 115
2024
Q4 		$5K Buy
+10,712
New +$7.87K ﹤0.01% 135

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stoneridge Investment Partners's LCTX Position: Q2 2026 in Review

Stoneridge Investment Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 12,540 shares — an estimated $20K sold.

Stoneridge Investment Partners first reported a position in LCTX in Q4 2024 and held it in 4 quarters. The position peaked at $21K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Stoneridge Investment Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stoneridge Investment Partners sold 12,540 Lineage Cell Therapeutics shares in Q2 2026, an estimated $20K.
  • Stoneridge Investment Partners first reported a position in Lineage Cell Therapeutics in Q4 2024 and held it in 4 quarters.
  • Stoneridge Investment Partners's Lineage Cell Therapeutics position peaked at $21K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.